August Troendle Sells 17,610 Shares of Medpace (NASDAQ:MEDP) Stock

Key Points

• CEO August Troendle sold 17,610 Medpace shares at an average price of $605.11, generating approximately $10.66 million. He retained 615,802 shares after the transaction, a 2.78% reduction in his holdings.
• Medpace shares fell 1.4% to $596.98, while the company reported quarterly EPS of $4.25 and revenue of $707.33 million, exceeding analyst estimates; revenue increased 17.2% year over year.
• Analysts maintain a consensus “Hold” rating, with an average price target of $584.18. Institutional investors own approximately 77.98% of Medpace’s outstanding stock.

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 17,610 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $605.11, for a total transaction of $10,655,987.10. Following the completion of the sale, the chief executive officer owned 615,802 shares in the company, valued at $372,627,948.22. This represents a 2.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Medpace Stock Down 1.4%

NASDAQ:MEDP traded down $8.52 on Wednesday, hitting $596.98. The stock had a trading volume of 310,338 shares, compared to its average volume of 355,204. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The business's 50-day simple moving average is $528.36 and its two-hundred day simple moving average is $491.85. The stock has a market cap of $16.66 billion, a price-to-earnings ratio of 34.99, a price-to-earnings-growth ratio of 2.69 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace's revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Jefferies Financial Group lowered shares of Medpace from a "buy" rating to a "hold" rating and increased their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. TD Cowen lifted their price target on shares of Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a report on Friday, July 24th. Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Robert W. Baird upped their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a research report on Friday, July 24th. Finally, Barclays set a $600.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Two equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $584.18.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP purchased a new stake in Medpace during the 2nd quarter valued at approximately $687,000. Evolve Private Wealth LLC purchased a new position in shares of Medpace in the second quarter worth $1,386,000. Westpac Banking Corp purchased a new position in shares of Medpace in the second quarter worth $437,000. Ieq Capital LLC bought a new position in shares of Medpace during the second quarter worth $20,323,000. Finally, Heron Bay Capital Management bought a new position in shares of Medpace during the second quarter worth $16,038,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source